Verus Capital Partners’s Edwards Lifesciences EW Stock Holding History

Verus Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$320K	Hold	4,000	–	–	0.02%	340
2025 Q4	$341K	Hold	4,000	–	–	0.02%	335
2025 Q3	$311K	Sell	4,000 -300	-7%	-$23.4K	0.02%	317
2025 Q2	$336K	Hold	4,300	–	–	0.03%	272
2025 Q1	$312K	Sell	4,300 -7	-0.2%	-$501	0.03%	275
2024 Q4	$319K	Buy	4,307 +7	+0.2%	+$490	0.03%	266
2024 Q3	$284K	Hold	4,300	–	–	0.03%	275
2024 Q2	$397K	Sell	4,300 -120	-3%	-$10.6K	0.04%	218
2024 Q1	$422K	Hold	4,420	–	–	0.05%	214
2023 Q4	$337K	Buy	4,420 +59	+1%	+$4.11K	0.04%	223
2023 Q3	$302K	Hold	4,361	–	–	0.04%	221
2023 Q2	$411K	Sell	4,361 -29	-0.7%	-$2.52K	0.06%	186
2023 Q1	$363K	Buy	4,390 +3	+0.1%	+$236	0.06%	198
2022 Q4	$327K	Buy	4,387 +57	+1%	+$4.39K	0.06%	197
2022 Q3	$358K	Buy	4,330 +2,977	+220%	+$286K	0.07%	187
2022 Q2	$414K	Sell	1,353 -2,967	-69%	-$307K	0.08%	179
2022 Q1	$434K	Buy	+4,320	New	+$485K	0.07%	207
2020 Q1	$277K	Sell	4,410 -300	-6%	-$21.6K	0.09%	144
2019 Q4	$366K	Buy	+4,710	New	+$368K	0.12%	133

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Verus Capital Partners's EW Position: Q1 2026 in Review

Verus Capital Partners held its Edwards Lifesciences (EW) position steady in Q1 2026 at 4,000 shares worth $320K. The position accounts for 0.02% of the portfolio, ranked #340.

Verus Capital Partners first reported a position in EW in Q4 2019 and has held it in 19 quarters since. The position peaked at $434K in Q1 2022. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Verus Capital Partners held 4,000 shares of Edwards Lifesciences worth $320K as of Q1 2026.
Verus Capital Partners left its Edwards Lifesciences share count unchanged in Q1 2026.
Edwards Lifesciences made up 0.02% of Verus Capital Partners's portfolio in Q1 2026, its #340 holding.
Verus Capital Partners first reported a position in Edwards Lifesciences in Q4 2019 and has held it in 19 quarters since.
Verus Capital Partners's Edwards Lifesciences position peaked at $434K in Q1 2022.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Verus Capital Partners's 13F filing for Q1 2026, filed 22 May 2026.